Adding a DPP-4 inhibitor to metformin therapy may be safer than you think

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.30, Iss.5, 2014-05, pp. : 791-794

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

By Graefe-Mody E. U. Padula S. Ring A. Withopf B. Dugi K. A.

Current Medical Research and Opinion, Vol. 25, Iss. 8, 2009-08 ,pp. : 1963-1972

Informa Healthcare

Access to resources Recommend Favorite

The future may be closer than you think: a response from the Personalized Medicine Coalition to the Royal Society’s report on personalized medicine

By Ginsburg Geoffrey S Angrist Misha

Personalized Medicine, Vol. 3, Iss. 2, 2006-05 ,pp. : 119-123

Future Medicine

Access to resources Recommend Favorite

Waardenburg syndrome: more common than you think!

CLINICAL OTOLARYNGOLOGY, Vol. 40, Iss. 1, 2015-02 ,pp. : 44-48

John Wiley & Sons Inc

Access to resources Recommend Favorite

Why ‘Safer than Ever’ May Not Be Quite Safe Enough

Transfusion Medicine and Hemotherapy, Vol. 31, Iss. 1, 2004-02 ,pp. : 2-10

Karger

Access to resources Recommend Favorite

Saxagliptin: a New DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

By Tahrani Abd Piya Milan Barnett Anthony

Advances in Therapy, Vol. 26, Iss. 7, 2009-07 ,pp. : 736-736

Springer Publishing Company

Access to resources Recommend Favorite